| Year |
Citation |
Score |
| 2024 |
Herrero Alvarez N, Molvi Z, Lupo K, Urraca J, Balderes P, Nyakatura EK, Khan AG, Viray T, Lewis JS, O'Reilly RJ. Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia. European Journal of Nuclear Medicine and Molecular Imaging. PMID 38987489 DOI: 10.1007/s00259-024-06814-7 |
0.445 |
|
| 2023 |
Molvi Z, Klatt MG, Dao T, Urraca J, Scheinberg DA, O'Reilly RJ. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal For Immunotherapy of Cancer. 11. PMID 37775115 DOI: 10.1136/jitc-2023-006889 |
0.553 |
|
| 2023 |
Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, Dao T, Scheinberg DA. Challenges and solutions for therapeutic TCR-based agents. Immunological Reviews. PMID 37455333 DOI: 10.1111/imr.13233 |
0.366 |
|
| 2023 |
Molvi Z, Klatt MG, Dao T, Urraca J, Scheinberg DA, O'Reilly RJ. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Biorxiv : the Preprint Server For Biology. PMID 36798179 DOI: 10.1101/2023.02.08.527552 |
0.552 |
|
| 2022 |
O'Reilly RJ, Molvi Z. CMV-specific T-cells following haploidentical transplants: reshaping a repertoire by half. Haematologica. PMID 36453111 DOI: 10.3324/haematol.2022.282132 |
0.445 |
|
| 2022 |
Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LMB, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, et al. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine. 14: eaba4380. PMID 35704596 DOI: 10.1126/scitranslmed.aba4380 |
0.449 |
|
| 2022 |
Bourne CM, Mun SS, Dao T, Aretz ZEH, Molvi Z, Gejman RS, Daman A, Takata K, Steidl C, Klatt MG, Scheinberg DA. Unmasking the suppressed immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas with combination drug treatment. Blood Advances. PMID 35561310 DOI: 10.1182/bloodadvances.2021006069 |
0.438 |
|
| 2022 |
Molvi Z, O'Reilly RJ. Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer. Cancer Treatment and Research. 183: 131-159. PMID 35551658 DOI: 10.1007/978-3-030-96376-7_4 |
0.552 |
|
| 2022 |
Dao T, Mun SS, Molvi Z, Korontsvit T, Klatt MG, Khan AG, Nyakatura EK, Pohl MA, White TE, Balderes PJ, Lorenz IC, O'Reilly RJ, Scheinberg DA. A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complex. Jci Insight. 7. PMID 35260532 DOI: 10.1172/jci.insight.151624 |
0.565 |
|
| 2021 |
Jones HF, Molvi Z, Klatt MG, Dao T, Scheinberg DA. Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in Immunology. 11: 585385. PMID 33569049 DOI: 10.3389/fimmu.2020.585385 |
0.489 |
|
| 2018 |
Deh K, Ponath GD, Molvi Z, Parel GT, Gillen KM, Zhang S, Nguyen TD, Spincemaille P, Ma Y, Gupta A, Gauthier SA, Pitt D, Wang Y. Magnetic susceptibility increases as diamagnetic molecules breakdown: Myelin digestion during multiple sclerosis lesion formation contributes to increase on QSM Journal of Magnetic Resonance Imaging. PMID 29517817 DOI: 10.1002/jmri.25997 |
0.181 |
|
| Show low-probability matches. |